X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

RETA

Closed

Reata Pharmaceuticals Inc

172.36
+0.04 (+0.02%)
Last Update: 26 Sep 2023 16:30:00
Yesterday: 172.32
Day's Range: 172.36 - 172.36
Send
When Written:
 
93.98
Reata Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for serious and rare diseases. The company was founded in 2002 and is headquartered in Irving, Texas.

Reata's lead product candidate is bardoxolone methyl, a potential treatment for various chronic diseases such as chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome. The company also has a pipeline of other drug candidates in various stages of development, including omaveloxolone for Friedreich's ataxia and neurological disorders, and RORγt inhibitors for autoimmune diseases.

Reata has partnerships with various pharmaceutical companies, including Kyowa Kirin Co. Ltd., AbbVie Inc., and Blackstone Life Sciences. The company has received funding from various sources, including venture capital firms, public offerings, and grants from the National Institutes of Health.

Reata is committed to advancing the development of innovative therapies for patients with unmet medical needs.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X